TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: NOVARTIND · data 2026-11-02
Evonile Pharma Limited
In plain words
Price: 31.9% below its 52-week high of ₹2,588.8.
Delivery: 42.3% of traded shares were kept for delivery over the last 10 sessions, against 46.1% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹371 cr |
| Net profit (last 12 months) | ₹98 cr |
| Sales growth, 3 years (yearly) | -2.2% |
| Profit growth, 3 years (yearly) | -3.4% |
At a glance
P/E 44.5, dividend yield 1.5%. Price relative to earnings and book value (low is cheaper, not better).
ROE 11.6%, ROCE 11.8%, operating margin 27.0%: how much profit it earns on the money it uses.
Debt/equity 0.00, Profit growth -3.4% and sales growth -2.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Healthy operating margin (27.0%).
- Profit fell 3.4% a year over 3 years.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
17/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 36.3% over the last 20 sessions vs 21.7% in the 40 before (1.67x); shares delivered per day 0.59x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 2/15: 1 scheme hold it, about ₹2 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Evonile Pharma Limited debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Evonile Pharma Limited's P/E ratio?
About 44.5, based on the last 12 months' earnings and a price of ₹1,763.8 (data 2026-11-02).
What is the 52-week high and low of Evonile Pharma Limited?
The 52-week high is ₹2,588.8 and the 52-week low is ₹950.
Mutual funds holding Evonile Pharma Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 1 scheme holding about ₹2 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 0.04% | ₹2 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Evonile Pharma Limited | ₹1,763.8 | ₹4,182 cr | 44.5 | — | 11.6% | 11.8% | 0 | +155.2% |
| Gujarat Themis Biosyn Ltd | ₹374.3 | ₹4,718 cr | 83.8 | — | 17.4% | 18.2% | 0.56 | -19.9% |
| RPG Life Sciences Limited | ₹2,521 | ₹4,255 cr | 34.9 | — | 20.3% | 21.3% | 0.03 | +5.3% |
| Gufic Biosciences Limited | ₹418.8 | ₹4,134 cr | 57.2 | — | 10.1% | 15.3% | 0.61 | +29.2% |
| Zota Health Care Ltd. | ₹1,297.2 | ₹4,031 cr | — | 7.2 | -16.1% | -9.7% | 0.39 | -16.5% |
| Aarti Drugs Limited | ₹449.45 | ₹3,977 cr | 21.5 | — | 13.4% | 13.2% | 0.37 | -10.4% |
Compare NOVARTIND with GUJTHEM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NOVARTIND in TickerKhoj →